A quantitative structure-activity relationship study of novel, potent, orally active, selective VEGFR-2 and PDGFRα tyrosine kinase inhibitors: Derivatives of N-Phenyl-N′-{4-(4-quinolyloxy)phenyl}urea as antitumor agents

References

• Folkman J. Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg 1972; 175: 409–416
   PubMed Web of Science ®Google Scholar
• Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels and pulmonary metastases following tumor implantation, Cancer Res 1974; 34: 997–1004
   Google Scholar
• Eckhardt SG. Angiogenesis inhibitors as cancer therapy. Hosp Pract 1999; 63–84
   Google Scholar
• Bergers G, Javaherian K, Lo K-M, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999; 284: 808–812
   PubMed Web of Science ®Google Scholar
• Fan T-PD, Jaggar R, Bicknell R. Controlling the vasculature: Angiogenesis, antiangiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16: 57–66
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841–844
   PubMed Web of Science ®Google Scholar
• Kolch W, Martiny-Baron G, Kieser A, Marme D. Regulation of the expression of VEGF/VPS and its receptors: Role in tumor angiogenesis. Breast Cancer Res Treat 1995; 36: 139–155
   PubMed Web of Science ®Google Scholar
• Leenders WPJ. Targetting VEGF in anti-angiogenic and anti-tumor therapy: Where are we now?. Int J Exp Pathol 1998; 79: 339–346
   PubMedGoogle Scholar
• Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullirich A, Hirth KP, Shawver LK. Fik-1 as a target for tumor growth inhibition. Cancer Res 1996; 56: 3540–3545
   PubMed Web of Science ®Google Scholar
• Millauer B, Longhi MP, Plate KH, Shawver LK, Risau W, Ullrich A, Strawn LM. Dominant-negative inhibition of Fik-1 suppresses the growth of many tumor types in vivo. Cancer Res 1996; 56: 1615–1620
   PubMed Web of Science ®Google Scholar
• Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993; 362: 841–844
   PubMed Web of Science ®Google Scholar
• Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hopper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 1999; 59: 5209–5218
   PubMed Web of Science ®Google Scholar
• Dumas J. Protein kinase inhibitors: Emerging pharmacophores 1997–2000. Exp Opin Ther Pat 2001; 11: 405–429
   Web of Science ®Google Scholar
• Connell RD, Beebe JS. Patent focus on cancer chemotherapeutics. II Angiogenesis agents: April 2000–September 2000. Exp Opin Ther Pat 2001; 11: 77–114
   Web of Science ®Google Scholar
• Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, Tang C. Synthesis and biological evaluations of 3-substituted Indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1998; 41: 2588–2603
   PubMed Web of Science ®Google Scholar
• Fong TAT, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Fik-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization and growth of multiple tumor types. Cancer Res 1999; 59: 99–106
   PubMed Web of Science ®Google Scholar
• Sun L, Tran N, Liang C, Tang F, Rice A, Schreck R, Waltz K, Shawver LK, McMahon G, Tang C. Design, synthesis and evaluation of substituted 3-[(3- or 4-carboxyethyl-pyrrol-2-yl)methyidenyl]indolin-2-ones as inhibitors of VEGF, FGF and PDGF receptor tyrosine kinases. J Med Chem 1999; 42: 5120–5130
   PubMed Web of Science ®Google Scholar
• Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TAT, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60: 4152–4160
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Thomas AP, Johnstone CE, Stokes ESE, Ple P, Lohmann J-JM, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Lambert-van-der-Brempt C. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. J Med Chem 1999; 42: 5369–5389
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Curwen JO, Hennequin LF, Thomas AP, Stokes ESE, Curry B, Richmond GH, Wadsworth PF. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broadspectrum antitumor efficacy. Cancer Res 2000; 60: 970–975
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Stokes ESE, Thomas AP, Johnstone C, Ple P, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO. Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure-activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002; 45: 1300–1312
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF, Bigley AL, Hennequin LF. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–4655
   PubMed Web of Science ®Google Scholar
• Bold G, Altmann K-H, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Bruggen J, Buchdunger E, Cozens R, Ferrari S, Furet P, Hofmann F, Martiny-Baron G, Mestan J, Rosel J, Sills M, Stover D, Acemoglu F, Boss E, Emmenegger R, Lasser L, Masso E, Roth R, Schlachter C, Vetterli W, Wyss D, Wood JM. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor driven angiogenesis. J Med Chem 2000; 43: 2310–2323
   PubMed Web of Science ®Google Scholar
• Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rosel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch K-H, Schneider MR, Drevs J, Martiny-Baron G, Totzke F, Marme D. PTK787/ZK222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60: 2178–2189
   PubMed Web of Science ®Google Scholar
• Fernand NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 39–50, 3 (Suppl 6)
   Google Scholar
• Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber JD, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 2003; 349: 427–434
   PubMed Web of Science ®Google Scholar
• Kubo K, Shimizu T, Ohyama S, Murooka H, Iwai A, Nakamura K, Hasegawa K, Kobayashi Y, Takahashi N, Takahashi K, Kato S, Izawa T, Isoe T. Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: Synthesis, structure-activity relationships and antitumor activities of N-Phenyl-N′-{4-(4-quinolyloxy)phenyl}ureas. J Med Chem 2005; 48: 1359–1366
   PubMed Web of Science ®Google Scholar
• Kubo K, Shimizu T, Ohyama S, Murooka H, Nishitoba T, Kato S, Kobayashi Y, Yagi M, Isoe T, Nakamura K, Osawa T, Izawa T. A novel series of 4-phenoxyquinolines:Potent and highly selective inhibitors of PDGF receptor autophosphorylation. Bioorg Med Chem Lett 1997; 23: 22935–22940
   Google Scholar
• Yagi M, Kato S, Kobayashi Y, Kubo K, Ohyama S, Shimizu T, Nishitoba T, Isoe T, Nakamura K, Ohashi H, Kobayashi N, Iinuma N, Osawa T, Onose R, Osada H. Selective inhibition of platelet-derived growth factor (PDGF) receptor autophosphory- lation and PDGF-mediated cellular events by quinoline derivatives. Exp Cell Res 1997; 234: 285–292
   PubMedGoogle Scholar
• Yagi M, Kato S, Kobayashi Y, Kobayashi N, Iinuma N, Nakamura K, Kubo K, Ohyama S, Murooka H, Shimizu T, Nishitoba T, Osawa T, Nagano N. Beneficial effects of a novel inhibition of platelet-derived growth factor receptor autophosphorylation in the rat with mesangial proliferative glomerulonephritis. Gen Pharmacol 1998; 31: 765–773
   PubMedGoogle Scholar
• Kubo K, Ohyama S, Shimizu T, Takami A, Murooka H, Nishitoba T, Kato S, Yagi M, Kobayashi Y, Iinuma N, Isoe T, Nakamura K, Iijima H, Osawa T, Izawa T. Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase. Bioorg Med Chem 2003; 11: 5117–5133
   PubMedGoogle Scholar
• ChemDraw Ultra 6.0 and Chem 3D Ultra, Cambridge Soft Corporation, Cambridge, USA.
   Google Scholar
• Hansch C, Leo A, Unger SH, Kim KH, Nikaitani D, Lien EJ. Aromatic substituents constants for structure-activity correlations. J Med Chem 1973; 16: 1207–1216
   PubMed Web of Science ®Google Scholar
• Unger SH, Hansch C. Quantitative models of steric effects. Prog Phys Org Chem 1976; 12: 91–118
   Google Scholar
• Hansh C, Leo A. Substituents constants for correlation analysis in chemistry and biology. John Wiley, New York 1979
   Google Scholar
• Wold S. Validation of QSAR's. Quant Struct-Act Relat 1991; 10: 191–193
   Web of Science ®Google Scholar
• Singh P, Kumar Rajesh, Sharma BK. Quantitative structure-activity relationship study of 5-iodo- and diaryl-analogues of tubercidin: Inhibitors of adenosine kinase. J Enz Inhib Med Chem 2003; 18: 395–402
   PubMed Web of Science ®Google Scholar